REN delivers where pharmacologic migraine therapy may leave gaps in acute and preventive care
There are millions of people who require a safe, effective, non-disruptive alternative that does not rely on pills or injections(1,2 Message Map). Nerivio® is the only FDA-cleared Remote Electrical Neuromodulation (REN) wearable for patients aged 8+ that offers clinically proven preventive and acute migraine treatment—delivering safe, effective results without medication or systemic side effects.
No Drugs
No Needles
Non-Addictive
Non-Sedative
Non-Invasive
No Rebound
Headaches
No Systemic
Side Effects
Insurance covered
Preventive &
Acute
FDA Cleared
Clinically
Proven
Safe
Effective
Discreet
Achieved pain relief with Nerivio
Demonstrated sustained pain relief and pain freedom at 24 hours
Achieved higher relief than with medication
Reduction of 4 migraine days per month
Experienced ≥50% reduction in moderate to severe headache days
No device-related adverse events reported in the clinical study
Achieved pain relief with Nerivio
Achieved pain freedom with Nerivio
Did not use prescription medications
Why the Nerivio REN wearable belongs in your frontline migraine care
Nerivio is designed to support adherence and fits seamlessly into patients’ daily lives. Incorporating Nerivio into early migraine management allows you to:
> Interrupt migraine progression before it becomes chronic
> Reduce medication reliance, especially for patients at risk for overuse headache
> Offer a safe and effective therapy for patients who can’t or won’t take medications
A novel mechanism of action
Nerivio works by stimulating the Aδ and C fibers in the upper arm, triggering the CPM system. This activates the descending inhibitory pain pathway allowing for the release of serotonin and norepinephrine, globally impacting pain.
The Nerivio patient profile
Nerivio may be an optimal migraine management option for your patients, particularly for those in the following populations:
> Children and adolescents (ages 8 and up)
> Adults with frequent or chronic migraine
> Patients managing comorbid conditions such as PTSD, anxiety, or depression
> Patients who require drug-free options due to occupational or clinical considerations
> Patients experiencing nausea or gastroparesis, where oral medications may be less effective
Insurance coverage
Broad coverage: Nerivio is covered by multiple health insurance plans, including state Medicaid programs.
Guaranteed coverage pathway and predictable costs: Many commercially and Medicaid-insured patients qualify for $0 full coverage. For other plans, insured patients pay $49 for their first device and $89 for refills, under the Nerivio Savings Program.
Hassle-Free Access: Insurance verification and patient support are handled seamlessly to ensure timely access to treatment.
Read What HCPs and Patients Say About Nerivio
Migraine is a life journey filled with both physical pain and emotional challenges. It often brings anxiety about the next attack, isolation, and other personal struggles that make coping even harder.
But it is also a journey of resilience and strength, where every moment of relief is a precious victory. We appreciate you, our users, for your perseverance, courage, and trust in us as your partners in your migraine management.
Start Offering Your Patients a Drug-Free, Clinically Proven Migraine Treatment
CTA Button: Explore Nerivio for Your Patients
